Selected Publications
van Oosterwijk JG, Tillman H, Sherr CJ. Sexually dimorphic tumor suppression by small mitochondrial Arf. Oncotarget Feb 8;10(12):1235-1237, 2019. doi: 10.18632/oncotarget.26651. eCollection 2019 Feb 8. PMID:30815226
Ruscetti M, Leibold J, Bott MJ, Fennell M, Kulick A, Salgado NR, Chen CC, Ho YJ, Sanchez-Rivera FJ, Feucht J, Baslan T, Tian S, Chen HA, Romesser PB, Poirier JT, Rudin CM, de Stanchina E, Manchado E, Sherr CJ, Lowe SW. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science Dec 21;362(6421):1416-1422, 2018. doi: 10.1126/science.aas9090. PMID: 30573629
Sherr CJ.Acquired palbociclib resistance in KRAS-mutant lung cancer. Oncotarget Aug 28;9(67):32734-32735, 2018. doi: 10.18632/oncotarget.26027. eCollection 2018 Aug 28. No abstract available. PMID:30214680
Vo BT, Kwon JA, Li C, Finkelstein D, Xu B, Orr BA, Sherr CJ, Roussel MF. Mouse medulloblastoma driven by CRISPR activation of cellular Myc. Sci Rep Jun 7;8(1):8733, 2018. doi: 10.1038/s41598-018-24956-1. PMID:29880921
van Oosterwijk JG, Li C, Yang X, Opferman JT, Sherr CJ. Small mitochondrial Arf (smArf) protein corrects p53-independent developmental defects of Arf tumor suppressor-deficient mice. Proc Natl Acad Sci U S A Jul 11;114(28):7420-7425, 2017. doi: 10.1073/pnas.1707292114. Epub 2017 Jun 26. PMID:28652370
Vo BT, Li C, Morgan MA, Theurillat I, Finkelstein D, Wright S, Hyle J, Smith SMC, Fan Y, Wang YD, Wu G, Orr BA, Northcott PA, Shilatifard A, Sherr CJ, Roussel MF. Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma. Cell Rep Mar 21;18(12):2907-2917, 2017. doi: 10.1016/j.celrep.2017.02.073. PMID:28329683
Sherr CJ. A New Cell-Cycle Target in Cancer - Inhibiting Cyclin D-Dependent Kinases 4 and 6. N Engl J Med Nov 17;375(20):1920-1923, 2016. PMID: 27959598
Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov 6(4):1-15, 2016. [EPub ahead of print 2015, PMID 26658964]
Sharpless NE, Sherr CJ. Forging a signature of in vivo senescence. Nat Rev Cancer 15(7):397-408, 2015.
Appelmann I, Rillahan CD, de Stanchina E, Carbonetti G, Chen C, Lowe SW, Sherr CJ. Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL. Blood 125(9):1444-1451, 2015.
Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev 28(16):1800-1814, 2014.
Li C, Qi R, Singleterry R, Hyle J, Balch A, Li X, Sublett J, Berns H, Valentine M, Valentine V, Sherr CJ. Simultaneous gene editing by injection of mRNAs encoding transcription activator-like effector nucleases into mouse zygotes. Mol Cell Biol 34(9):1649-1658, 2014.
Li C, Finkelstein D, Sherr CJ. Arf tumor suppressor and miR-205 regulate cell adhesion and formation of extraembryonic endoderm from pluripotent stem cells. Proc Natl Acad Sci USA 110(12):E1112-1121, 2013.
Sherr CJ. Ink4-Arf locus in cancer and aging. Wiley Interdiscip Rev Dev Biol (WIRES) 1(5):731-741, 2012.
Treanor LM, Volanakis EJ, Zhou S, Lu T, Sherr CJ, Sorrentino BP. Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies. Blood 117(20):5453-5462, 2011.
Boulos N, Mulder HL, Calabrese CR, Morrison JB, Rehg JE, Relling MV, Sherr CJ, Williams RT. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 117(13):3585-3595, 2011.
Last update: June 2019